It's interesting that the CEO prefers more variable cost in a fast growing business. Intuitively you'd say it'd slow their path to profitability, but I'll go along with it for now.
Presume he felt some/most of the sales team were underperforming vs their salary element, sounds like they were chasing smaller accounts closer to home, instead of going after bigger fish further away. He did say there's a big difference among payors.
"... improvement in revenue quality [but] suboptimal salesforce coverage of existing territories resulting in poor productivity."
I assume "quality" means repeatability.
If it was growing 50-100% with some sales laggards (albeit it off a small base), then I'm interested to see what a full team of properly motivated salespeople can do. The previous numbers suggested the product sold itself - with the right effort - and I can't see that much has changed in that regard.
Anyone keeping tabs on the competition?
- Forums
- ASX - By Stock
- Ann: Appendix 4C & Quarterly Activity Report - 31 March 2024
It's interesting that the CEO prefers more variable cost in a...
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NXS (ASX) to my watchlist
(20min delay)
|
|||||
Last
35.0¢ |
Change
0.020(6.06%) |
Mkt cap ! $102.0M |
Open | High | Low | Value | Volume |
33.5¢ | 35.0¢ | 32.0¢ | $67.36K | 197.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 25000 | 35.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
35.5¢ | 25000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 23480 | 0.340 |
2 | 28469 | 0.330 |
2 | 15000 | 0.325 |
2 | 112500 | 0.320 |
8 | 281674 | 0.310 |
Price($) | Vol. | No. |
---|---|---|
0.350 | 1700 | 1 |
0.355 | 25000 | 1 |
0.360 | 40000 | 1 |
0.365 | 2739 | 1 |
0.370 | 3075 | 1 |
Last trade - 13.01pm 06/05/2024 (20 minute delay) ? |
|
|||||
Last
35.0¢ |
  |
Change
0.020 ( 9.38 %) |
|||
Open | High | Low | Volume | ||
33.0¢ | 35.0¢ | 32.0¢ | 46457 | ||
Last updated 14.32pm 06/05/2024 ? |
Featured News
NXS (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Steven Gourlay, CEO
Steven Gourlay
CEO
Previous Video
Next Video
SPONSORED BY The Market Online